IMPLANTICA AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30 SEK | -0.17% |
|
+0.50% | +25.52% |
| May. 15 | Transcript : Implantica AG, Q1 2024 Earnings Call, May 15, 2024 | |
| May. 15 | Tranche Update on Implantica AG (OM:IMP A SDB)'s Equity Buyback Plan announced on April 6, 2023. | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,296 | 1,798 | 1,010 | 607.6 | 745.5 | - | - |
| Enterprise Value (EV) 1 | 4,199 | 1,714 | 901.5 | 519.7 | 694.6 | 694.7 | 720.6 |
| P/E ratio | -1,559 x | -27.6 x | -11.9 x | -6.31 x | -4.18 x | -4.09 x | -7.77 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 28,266 x | 4,647 x | 1,200 x | 432 x | 207 x | 72.1 x | 23.4 x |
| EV / Revenue | 27,624 x | 4,429 x | 1,071 x | 369 x | 193 x | 67.1 x | 22.7 x |
| EV / EBITDA | -457 x | -146 x | -53.8 x | -25.7 x | -21.6 x | -16.1 x | -32.9 x |
| EV / FCF | -346,642,696 x | -101,345,928 x | -56,277,398 x | - | - | - | - |
| FCF Yield | -0% | -0% | -0% | - | - | - | - |
| Price to Book | 153 x | 2.3 x | 1.29 x | 0.98 x | 1.73 x | 2.13 x | 2.94 x |
| Nbr of stocks (in thousands) | 275,673 | 283,112 | 283,112 | 283,082 | 283,110 | - | - |
| Reference price 2 | 15.59 | 6.352 | 3.568 | 2.147 | 2.633 | 2.633 | 2.633 |
| Announcement Date | 2/25/21 | 2/18/22 | 2/17/23 | 2/16/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.152 | 0.387 | 0.842 | 1.408 | 3.6 | 10.35 | 31.82 |
| EBITDA 1 | -9.197 | -11.73 | -16.76 | -20.22 | -32.21 | -43.06 | -21.91 |
| EBIT 1 | -10.64 | -13.14 | -18.45 | -21.84 | -32.61 | -43.45 | -22.31 |
| Operating Margin | -7,000.66% | -3,395.61% | -2,190.86% | -1,551.14% | -905.7% | -420% | -70.11% |
| Earnings before Tax (EBT) 1 | -10.32 | -15.45 | -21.4 | -24.43 | -36.5 | -46.45 | -24.44 |
| Net income 1 | -10.28 | -15.36 | -20.82 | -23.74 | -36.62 | -46.55 | -24.51 |
| Net margin | -6,761.18% | -3,969.25% | -2,473.16% | -1,686.36% | -1,017.33% | -449.9% | -77.05% |
| EPS 2 | -0.0100 | -0.2300 | -0.3000 | -0.3400 | -0.6305 | -0.6432 | -0.3387 |
| Free Cash Flow | -12.11 | -16.91 | -16.02 | - | - | - | - |
| FCF margin | -7,969.08% | -4,370.28% | -1,902.49% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 2/25/21 | 2/18/22 | 2/17/23 | 2/16/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.107 | 0.198 | 0.207 | 0.195 | 0.242 | 0.307 | 0.349 | 0.244 | 0.508 | 0.596 | 0.9 | 1.26 | 0.9 |
| EBITDA 1 | -3.638 | -3.986 | -3.921 | -4.149 | -4.702 | -4.469 | -3.873 | -5.345 | -6.529 | -6.78 | -8.052 | -7.71 | -8.052 |
| EBIT 1 | -3.99 | -4.411 | -4.347 | -4.581 | -5.108 | -4.87 | -4.276 | -5.752 | -6.942 | -7.087 | -8.152 | -7.809 | -8.151 |
| Operating Margin | -3,728.97% | -2,227.78% | -2,100% | -2,349.23% | -2,110.74% | -1,586.32% | -1,225.21% | -2,357.38% | -1,366.54% | -1,189.09% | -905.75% | -619.8% | -905.7% |
| Earnings before Tax (EBT) 1 | -5.441 | -4.902 | -5.828 | -5.886 | -4.784 | -4.769 | -5.289 | -5.689 | -8.681 | -3.47 | -9.009 | -8.974 | -9.124 |
| Net income 1 | -6.254 | -4.776 | -5.762 | -5.66 | -4.626 | - | -5.173 | -5.442 | -8.577 | -3.364 | -9.04 | -9.011 | -9.156 |
| Net margin | -5,844.86% | -2,412.12% | -2,783.57% | -2,902.56% | -1,911.57% | - | -1,482.23% | -2,230.33% | -1,688.39% | -564.43% | -1,004.4% | -715.15% | -1,017.33% |
| EPS 2 | -0.0900 | -0.0700 | -0.0800 | -0.0800 | -0.0700 | -0.0700 | -0.0700 | -0.0800 | -0.1200 | -0.0500 | -0.1556 | -0.1551 | -0.1576 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/18/22 | 5/11/22 | 8/23/22 | 11/15/22 | 2/17/23 | 5/12/23 | 8/24/23 | 11/22/23 | 2/16/24 | 4/26/24 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 97.5 | 84.3 | 109 | 87.9 | 50.9 | 50.8 | 24.9 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | -12.1 | -16.9 | -16 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.1000 | 2.760 | 2.760 | 2.190 | 1.520 | 1.230 | 0.9000 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | 1.72 | 5.44 | 0.06 | - | - | - | - |
| Capex / Sales | 1,130.26% | 1,405.94% | 7.24% | - | - | - | - |
| Announcement Date | 2/25/21 | 2/18/22 | 2/17/23 | 2/16/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.633
EUR
Average target price
3.834
EUR
Spread / Average Target
+45.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.52% | 806M | |
| -24.88% | 7.32B | |
| +7.04% | 6.66B | |
| +15.10% | 5.5B | |
| -15.87% | 4.88B | |
| +14.96% | 4.1B | |
| -21.75% | 3.89B | |
| -25.03% | 2.83B | |
| +44.01% | 2.31B | |
| +1.98% | 2.07B |
- Stock Market
- Equities
- IMP A SDB Stock
- Financials Implantica AG
